The Peptide Process Development & CMC Summit is a key event for peptide synthesis and development professionals. Highlighting advancements like Novo Nordisk’s $6 billion peptide investment and Merck’s macrocyclic peptides, the summit addresses the growing demand for complex peptides and large-scale manufacturing.

Attendees will learn advanced synthesis techniques, optimize traditional methods, explore alternative processes, understand regulatory requirements, and scale up manufacturing for clinical development. This industry-led event, featuring experts from Amgen, Lilly, Merck, and Novartis, is the only summit dedicated to synthetic peptide process development and CMC. The summit will take place this July, bringing together experts to revolutionize peptide-driven drug development.

Bachem is attending this event.